Nefopam Panpharma (Nefopam Hydrochloride)

Nefopam produces analgesia by inhibiting the reuptake of norepinephrine, serotonin, and dopamine, and by blocking sodium channels in the central nervous system. This multimodal action enhances descending inhibitory pathways and reduces neuronal excitability, providing pain relief without engaging opioid receptors.

The specific dose and infusion rate of Nefopam Panpharma are determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals adjust the regimen to achieve adequate analgesia while monitoring for adverse effects.

Safety data for nefopam in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Unlike opioids, nefopam does not act on μ‑opioid receptors, so it avoids typical opioid‑related side effects such as respiratory depression, constipation, and dependence. It provides comparable analgesia for moderate pain but may cause different adverse effects like sweating or tachycardia, and it is not suitable for severe pain that requires opioid potency.

Nefopam Panpharma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and ensure the vial is kept sealed until use.

The medication is supplied as an injectable solution for intramuscular or intravenous administration. It is typically given by a healthcare professional in a clinical setting, with the infusion rate and total dose determined by the prescriber based on the patient’s pain level and clinical response.

Serious risks include seizures, severe hypotension, cardiac arrhythmias, and rare anaphylactic reactions. Patients with a history of seizures, uncontrolled hypertension, or known hypersensitivity to nefopam should be closely monitored, and immediate medical attention is required if any of these events occur.

Nefopam Panpharma is contraindicated in patients taking monoamine oxidase inhibitors, those with a known hypersensitivity to nefopam, and individuals with uncontrolled epilepsy or severe cardiovascular instability. It should also be used with caution in pregnant or breastfeeding women, and in patients with significant renal or hepatic impairment.